Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Europeiska unionen - svenska - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrelhydroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiska medel - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Europeiska unionen - svenska - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogrelbesilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotiska medel - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segmentet höjd akut hjärtinfarkt, i kombination med asa i medicinskt behandlade patienter berättigade till trombolysbehandling. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. för ytterligare information hänvisas till avsnitt 5.

Algesal 100 mg/g Salva Sverige - svenska - Läkemedelsverket (Medical Products Agency)

algesal 100 mg/g salva

bgp products ab - dietylaminsalicylat - salva - 100 mg/g - dietylaminsalicylat 100 mg aktiv substans - salicylsyraderivat

Klacid 25 mg/ml Granulat till oral suspension Sverige - svenska - Läkemedelsverket (Medical Products Agency)

klacid 25 mg/ml granulat till oral suspension

bgp products ab - klaritromycin - granulat till oral suspension - 25 mg/ml - klaritromycin 25 mg aktiv substans; kaliumsorbat hjälpämne; sackaros hjälpämne - klaritromycin

Klacid 250 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

klacid 250 mg tablett

bgp products ab - klaritromycin - tablett - 250 mg - klaritromycin 250 mg aktiv substans; sorbinsyra hjälpämne; propylenglykol hjälpämne - klaritromycin

Klacid 500 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

klacid 500 mg tablett

bgp products ab - klaritromycin - tablett - 500 mg - sorbinsyra hjälpämne; propylenglykol hjälpämne; klaritromycin 500 mg aktiv substans - klaritromycin

Duphalac Frukt 667 mg/ml Oral lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

duphalac frukt 667 mg/ml oral lösning

bgp products ab - laktulos - oral lösning - 667 mg/ml - laktos (vattenfri) hjälpämne; laktulos 667 mg aktiv substans - laktulos

Creon 40000 Enterokapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

creon 40000 enterokapsel, hård

bgp products ab - pankreaspulver - enterokapsel, hård - natriumlaurilsulfat hjälpämne; cetylalkohol hjälpämne; pankreaspulver 400 mg aktiv substans - proteas m.fl.)

Rytmonorm 300 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

rytmonorm 300 mg filmdragerad tablett

bgp products ab - propafenonhydroklorid - filmdragerad tablett - 300 mg - propafenonhydroklorid 300 mg aktiv substans - propafenon

Isoptin 120 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

isoptin 120 mg filmdragerad tablett

bgp products ab - verapamilhydroklorid - filmdragerad tablett - 120 mg - verapamilhydroklorid 120 mg aktiv substans; natriumlaurilsulfat hjälpämne - verapamil